aids vaccines

Summary

Summary: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.

Top Publications

  1. ncbi Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission
    Cynthia A Derdeyn
    Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294 USA
    Science 303:2019-22. 2004
  2. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
  3. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    Barton F Haynes
    Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
    N Engl J Med 366:1275-86. 2012
  4. pmc Broad neutralization coverage of HIV by multiple highly potent antibodies
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 477:466-70. 2011
  5. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
  6. pmc Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
    Jason S McLellan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 480:336-43. 2011
  7. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
  8. pmc HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
    Michael R Betts
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 107:4781-9. 2006
  9. pmc Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
  10. pmc Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Science 329:811-7. 2010

Detail Information

Publications263 found, 100 shown here

  1. ncbi Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission
    Cynthia A Derdeyn
    Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294 USA
    Science 303:2019-22. 2004
    ..This reveals characteristics of the envelope glycoprotein that influence HIV-1 transmission and may have implications for vaccine design...
  2. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
    ..The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control...
  3. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    Barton F Haynes
    Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
    N Engl J Med 366:1275-86. 2012
    ..In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk...
  4. pmc Broad neutralization coverage of HIV by multiple highly potent antibodies
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 477:466-70. 2011
    ....
  5. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
    ..The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses...
  6. pmc Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
    Jason S McLellan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 480:336-43. 2011
    ..In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand...
  7. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
    ..Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design...
  8. pmc HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
    Michael R Betts
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 107:4781-9. 2006
    ..Thus, rather than quantity or phenotype, the quality of the CD8(+) T-cell functional response serves as an immune correlate of HIV disease progression and a potential qualifying factor for evaluation of HIV vaccine efficacy...
  9. pmc Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
    ....
  10. pmc Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Science 329:811-7. 2010
    ..Partial receptor mimicry and extensive affinity maturation thus facilitate neutralization of HIV-1 by natural human antibodies...
  11. pmc Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
    Susan P Buchbinder
    HIV Research Section, San Francisco Department of Public Health, San Francisco, CA, USA
    Lancet 372:1881-93. 2008
    ..The Step Study directly assessed the efficacy of a cell-mediated immunity vaccine to protect against HIV-1 infection or change in early plasma HIV-1 levels...
  12. pmc Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing
    Xueling Wu
    Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Science 333:1593-602. 2011
    ....
  13. pmc Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
    Scott G Hansen
    Vaccine and Gene Therapy Institute, Department of Molecular Microbiology, Oregon Health and Science University, Beaverton, Oregon 97006, USA
    Nature 473:523-7. 2011
    ..Thus, persistent vectors such as CMV and their associated T(EM) responses might significantly contribute to an efficacious HIV/AIDS vaccine...
  14. pmc Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    Ming Li
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 79:10108-25. 2005
    ..These reference reagents will facilitate proficiency testing and other validation efforts aimed at improving assay performance across laboratories and can be used for standardized assessments of vaccine-elicited neutralizing antibodies...
  15. pmc Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
    Ann J Hessell
    Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA
    PLoS Pathog 5:e1000433. 2009
    ..The results raise the possibility that some epitopes on HIV may be better vaccine targets than others and support targeting the glycan shield of the envelope...
  16. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
    ..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options...
  17. pmc Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 482:89-93. 2012
    ..These data demonstrate the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys...
  18. pmc The immune response during acute HIV-1 infection: clues for vaccine development
    Andrew J McMichael
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Nat Rev Immunol 10:11-23. 2010
    ..In this Review, we discuss recent studies on the kinetics and quality of early immune responses to HIV-1 and their implications for developing a successful preventive HIV-1 vaccine...
  19. pmc Induction of immunity to human immunodeficiency virus type-1 by vaccination
    M Juliana McElrath
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3 100, Seattle, WA 98109, USA
    Immunity 33:542-54. 2010
    ....
  20. pmc HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
    M Juliana McElrath
    Vaccine and Infectious Disease Institute and the HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Lancet 372:1894-905. 2008
    ..We assessed vaccine-induced immunity and its potential contributions to infection risk...
  21. pmc Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
    J R Mascola
    Division of Retrovirology, Walter Reed Army Institute of Research and Henry M Jackson Foundation, Rockville, Maryland 20850, USA
    J Virol 73:4009-18. 1999
    ..These data indicate a general correlation between in vitro neutralization and protection and suggest that a vaccine that elicits neutralizing antibody should have a protective effect against HIV-1 infection or disease...
  22. ncbi The role of antibodies in HIV vaccines
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Immunol 28:413-44. 2010
    ..Thus, current vaccine design efforts have focused on a more detailed understanding of these broadly neutralizing antibodies and their epitopes to inform the design of improved vaccines...
  23. pmc Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    James M Binley
    IMM2, Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 78:13232-52. 2004
    ..As well as the significance for vaccine design, our data have implications for passive-immunization studies in countries where clade C viruses are common, given that only MAbs b12 and 4E10 were effective against viruses from this clade...
  24. ncbi Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
    Leonidas Stamatatos
    1Seattle Biomedical Research Institute, Seattle, Washington, USA
    Nat Med 15:866-70. 2009
    ..A concerted effort of structure-based vaccine design will help guide the development of improved antibody-based vaccines for HIV-1...
  25. pmc Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
    David C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 206:431-41. 2012
    ..No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials...
  26. pmc Design and pre-clinical evaluation of a universal HIV-1 vaccine
    Sven Létourneau
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford, United Kingdom
    PLoS ONE 2:e984. 2007
    One of the big roadblocks in development of HIV-1/AIDS vaccines is the enormous diversity of HIV-1, which could limit the value of any HIV-1 vaccine candidate currently under test.
  27. ncbi Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    Punnee Pitisuttithum
    Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    J Infect Dis 194:1661-71. 2006
    ....
  28. pmc Lessons learned from HIV-1 vaccine trials: new priorities and directions
    Andrew J McMichael
    Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK
    Nat Immunol 13:423-7. 2012
    ..There is understanding of what makes HIV envelope-specific antibodies broadly neutralizing and new T cell vaccine approaches can overcome virus variability...
  29. ncbi Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Barton F Haynes
    Duke University School of Medicine, Durham, NC 27710, USA
    Science 308:1906-8. 2005
    ..These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines...
  30. pmc HIV-1 group M conserved elements vaccine
    Morgane Rolland
    Department of Microbiology, University of Washington School of Medicine, Seattle, Washington, United States of America
    PLoS Pathog 3:e157. 2007
  31. ncbi Evolutionary and immunological implications of contemporary HIV-1 variation
    B Korber
    Division of Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico 98545, USA
    Br Med Bull 58:19-42. 2001
    ..The impact of HIV-1 variation on host immune response is reviewed in this context...
  32. pmc Rational antibody-based HIV-1 vaccine design: current approaches and future directions
    Laura M Walker
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
    Curr Opin Immunol 22:358-66. 2010
    ....
  33. ncbi A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120
    Simon Beddows
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, Room W 805, New York, NY 10021, USA
    Virology 360:329-40. 2007
    ..When antibodies able to neutralize HIV-1(JR-FL) were detected, antigen depletion studies showed they were not directed at the V3 region but were targeted at other, undefined gp120 and also non-gp120 epitopes...
  34. ncbi Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges
    Morgane Bomsel
    Mucosal Entry of HIV 1 and Mucosal Immunity, Cell Biology and Host Pathogen Interactions Department, Cochin Institute, CNRS UMR 8104, 22 rue Mechain, Paris, France
    Immunity 34:269-80. 2011
    ..The protection observed challenges the paradigm whereby circulating antiviral antibodies are required for protection against HIV-1 infection and may serve in designing a human vaccine against HIV-1-AIDS...
  35. ncbi Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression
    Jonah B Sacha
    Wisconsin National Primate Research Center, University of Wisconsin Madison, Madison, WI 53711, USA
    J Immunol 178:2746-54. 2007
    ..0017) in SIV-infected rhesus macaques. These results suggest that HIV vaccines should focus CD8(+) T cell responses on Gag...
  36. pmc The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope
    Mark S de Souza
    U S Military HIV Research Program U S Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok 10400, Thailand
    J Immunol 188:5166-76. 2012
    ..Although the RV144 T cell responses were modest in frequency compared with humoral immune responses, the CD4(+) T cell response was directed to HIV-1 Env and more particularly the V2 region...
  37. pmc HIV vaccines: lessons learned and the way forward
    Jerome H Kim
    Walter Reed Army Institute of Research, U S Military HIV Research Program, Rockville, Maryland, USA
    Curr Opin HIV AIDS 5:428-34. 2010
    ..An effective HIV vaccine is a global health priority. We describe lessons learned from four HIV vaccine trials that failed to demonstrate efficacy and one that showed modest protection as a pathway forward...
  38. ncbi Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
    Will Fischer
    Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
    Nat Med 13:100-6. 2007
    HIV-1/AIDS vaccines must address the extreme diversity of HIV-1...
  39. ncbi A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study
    Flavia Ferrantelli
    National AIDS Center, Istituto Superiore di Sanita, Viale Regina Elena, 299 00161 Rome, Italy
    Vaccine 29:2918-32. 2011
    ....
  40. pmc Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design
    Susan Zolla-Pazner
    Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York 10010, USA
    Nat Rev Immunol 10:527-35. 2010
    ..Recombinant immunogens that include these features may provide the means to address the antigenic diversity of HIV-1 and induce protective antibodies that can prevent infection with HIV-1...
  41. pmc Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies
    Delphine C Malherbe
    Oregon National Primate Center, Oregon Health and Science University, Beaverton, Oregon 97006, USA
    J Virol 85:5262-74. 2011
    ....
  42. pmc Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial
    Susan Zolla-Pazner
    Research Service, Veterans Affairs Medical Center, New York, New York, United States of America
    PLoS ONE 8:e53629. 2013
    ....
  43. ncbi Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques
    Maximillian Rosario
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, Oxford, UK
    Eur J Immunol 40:1973-84. 2010
    ..Thus, by improving both the HIV-1-derived immunogen and vector regimen/delivery, this approach could induce stronger, broader, and theoretically more protective T-cell responses than vaccines previously used in humans...
  44. pmc Replicating and non-replicating viral vectors for vaccine development
    Marjorie Robert-Guroff
    National Institutes of Health, National Cancer Institute, Vaccine Branch, 41 Medlars Drive, Building 41, Room D804, Bethesda, MD 20892 5065, United States
    Curr Opin Biotechnol 18:546-56. 2007
    ..Here several viral vectors under development as HIV/AIDS vaccines are reviewed...
  45. pmc B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study
    Barton F Haynes
    Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
    Nat Biotechnol 30:423-33. 2012
    ..This approach, which should be applicable to many infectious agents, holds promise for the construction of vaccines that can drive B cells along rare but desirable maturation pathways...
  46. pmc Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein
    Juliana Falivene
    Centro Nacional de Referencia para el SIDA, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
    PLoS ONE 7:e32220. 2012
    ..The aim of this study was to evaluate cellular immune responses (CIR) induced by an IL-18 binding protein gene (C12L) deleted vector (MVAΔC12L)...
  47. pmc Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody
    Dennis R Burton
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 108:11181-6. 2011
    ..A nonneutralizing antibody to gp41 may have a limited capacity to protect, but the results suggest that the central focus of HIV-1 vaccine research should be on the induction of potently neutralizing antibodies...
  48. pmc Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)
    Ann Duerr
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109 1024, USA
    J Infect Dis 206:258-66. 2012
    ..Follow-up was extended to assess relative risk of HIV acquisition in vaccinees vs placebo recipients over time...
  49. ncbi CD8(+) T cells in preventing HIV infection and disease
    Adrian B McDermott
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    AIDS 26:1281-92. 2012
    ..In the context of previous clinical HIV/AIDS vaccine trials, we consider the challenges faced by therapeutic and vaccine strategies designed to elicit effective HIV-specific CD8 T cells...
  50. pmc Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
    Barbara J Flynn
    Vaccine Research Center and Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 108:7131-6. 2011
    ..These data reveal qualitative differences in antibody and T-cell responses to DEC-HIV Gag p24 and Gag p24 protein and show that prime boost with protein and adjuvant followed by NYVAC elicits potent cellular immunity...
  51. pmc Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses
    Dennis R Burton
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Science 337:183-6. 2012
    ..Molecular characterizations of the antibodies and, most importantly, of the sites of vulnerability that they recognize give hope for the discovery of new vaccines and drugs...
  52. ncbi Cellular immune responses to HIV
    A J McMichael
    MRC Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Nature 410:980-7. 2001
    ..The failure of the latter to function efficiently facilitates the escape of virus from immune control and the collapse of the whole immune system...
  53. pmc Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate
    Jeffrey R Currier
    United States Military HIV Research Program, Rockville, Maryland, United States of America
    PLoS ONE 5:e13983. 2010
    ..The HIV sequences were derived from circulating recombinant form CRF01_AE, which predominates in Thailand. The objective was to evaluate safety and immunogenicity of MVA-CMDR in human volunteers in the US and Thailand...
  54. ncbi Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
    Peter B Gilbert
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Infect Dis 191:666-77. 2005
    ....
  55. ncbi Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults
    Frances H Priddy
    Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    Clin Infect Dis 46:1769-81. 2008
    ....
  56. pmc Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Nat Med 16:319-23. 2010
    ..Polyvalent mosaic antigens therefore represent a promising strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such as HIV-1...
  57. pmc Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures
    Audray Harris
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 108:11440-5. 2011
    ....
  58. pmc New paradigms for HIV/AIDS vaccine development
    Louis J Picker
    Vaccine and Gene Therapy Institute, Department of Molecular Microbiology, Oregon Health and Science University, Beaverton, Oregon 97006, USA
    Annu Rev Med 63:95-111. 2012
    ....
  59. pmc Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine
    Nicole Frahm
    Vaccine and Infectious Disease Division and HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Clin Invest 122:359-67. 2012
    ..These findings provide what we believe to be a new understanding of how preexisting viral immunity may impact the efficacy of vaccines under current evaluation for prevention of HIV, tuberculosis, and malaria...
  60. pmc Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study
    Fusheng Li
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 6:e20479. 2011
    ..Development of vaccine strategies that can elicit a greater breadth of responses, and towards conserved regions of the genome in particular, are critical requirements for effective T-cell based vaccines against HIV-1...
  61. pmc Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions
    Juan García-Arriaza
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Cientificas CSIC, Madrid, Spain
    PLoS ONE 5:e12395. 2010
    ....
  62. pmc Novel adenovirus vector-based vaccines for HIV-1
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Curr Opin HIV AIDS 5:386-90. 2010
    ..These vectors are being explored as potential vaccine candidates for a variety of pathogens. This review summarizes current efforts to develop rAd vector-based vaccines for HIV-1...
  63. ncbi Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
    Neil M Flynn
    University of California at Davis Medical Center, USA
    J Infect Dis 191:654-65. 2005
    ..A vaccine is needed to prevent human immunodeficiency virus type 1 (HIV-1) infection...
  64. ncbi Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope
    Bruno E Correia
    Department of Biochemistry, University of Washington, Seattle, WA 98195, USA
    Structure 18:1116-26. 2010
    ..The results demonstrate that computationally designed epitope-scaffolds are valuable as structure-specific serological reagents and as immunogens to elicit antibodies with predetermined structural specificity...
  65. pmc The changing face of HIV vaccine research
    Peter D Kwong
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Int AIDS Soc 15:17407. 2012
    ..This article summarizes challenges to the development of an HIV-1 vaccine, lessons learned from scientific investigation and completed vaccine trials, and promising developments in HIV-1 vaccine design...
  66. pmc Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs
    Sam Hoot
    Seattle Biomedical Research Institute, Seattle, WA, USA
    PLoS Pathog 9:e1003106. 2013
    ..Our study also highlights the need for intense efforts to identify rare naturally occurring or engineered Envs that may engage the germline BCR versions of bNAbs...
  67. pmc Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study
    Glenda E Gray
    Perinatal HIV Research Unit, University of Witwatersrand, Johannesburg, South Africa
    Lancet Infect Dis 11:507-15. 2011
    ..We aim to assess the safety and efficacy of the vaccine in South Africa, where the major circulating clade is subtype C...
  68. pmc Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults
    Spyros A Kalams
    Division of Infectious Diseases, Department of Medicine, Department of Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of Ameica
    PLoS ONE 7:e29231. 2012
    ..DNA vaccines are a promising approach to vaccination since they circumvent the problem of vector-induced immunity. DNA plasmid cytokine adjuvants have been shown to augment immune responses in small animals and in macaques...
  69. pmc Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Virology 427:198-207. 2012
    ..The data suggest the presence of shared, conserved structural elements in the V2 loop, and these can be used in the design of vaccine immunogens inducing broadly reactive Abs with anti-viral activities...
  70. pmc Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial
    Morgane Rolland
    Department of Microbiology, University of Washington, Seattle, Washington, USA
    Nat Med 17:366-71. 2011
    ..These results represent what is to our knowledge the first evidence of selective pressure from vaccine-induced T cell responses on HIV-1 infection in humans...
  71. pmc Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)
    Dan H Barouch
    Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Infect Dis 207:248-56. 2013
    ..ENVA.01), are reported concurrently with this article. Here, we characterize in greater detail the humoral and cellular immune responses elicited by Ad26.ENVA.01 in humans...
  72. pmc Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1
    Brandon F Keele
    University of Alabama at Birmingham, Birmingham, AL 35223, USA
    J Exp Med 206:1117-34. 2009
    ..These findings identify key similarities in mucosal transmission and early diversification between SIV and HIV-1, and thus validate the SIV-macaque mucosal infection model for HIV-1 vaccine and microbicide research...
  73. pmc Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses
    Yun Li
    Washington National Primate Center, University of Washington, 3000 Western Ave, Seattle, WA 98121, USA
    J Virol 82:638-51. 2008
    ..These results indicate the potential advantages for glycan modification in vaccine design, although the role of specific glycans requires further examination...
  74. ncbi Limitations to the structure-based design of HIV-1 vaccine immunogens
    Marc H V Van Regenmortel
    Institut de Recherche de l Ecole de Biotechnologie de Strasbourg, CNRS UdS, Strasbourg, France
    J Mol Recognit 24:741-53. 2011
    ..It is concluded that only trial and error, empirical investigations using numerous immunization protocols may eventually allow us to identify which mixtures of immunogens are likely to be the best candidates for an HIV-1 vaccine...
  75. pmc Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1
    Adel Benlahrech
    Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom
    Proc Natl Acad Sci U S A 106:19940-5. 2009
    ....
  76. pmc Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens
    Xiaodong Xiao
    Protein Interactions Group, CCRNP, NCI Frederick, NIH, Frederick, MD 21702, USA
    Biochem Biophys Res Commun 390:404-9. 2009
    ..This hypothesis, if further supported by data, could contribute to our understanding of how HIV-1 evades immune responses and offer new concepts for design of effective vaccine immunogens...
  77. pmc The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens
    Carmen Elena Gómez
    Centro Nacional de Biotecnologia, CSIC, Madrid 28049, Spain
    J Virol 85:11468-78. 2011
    ..Thus, on the basis of the immune profile of MVA-B in humans, this immunogen can be considered a promising HIV/AIDS vaccine candidate...
  78. pmc A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses
    Juan García-Arriaza
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Cientificas CSIC, Madrid, Spain
    PLoS ONE 6:e24244. 2011
    ..Our observations are relevant for the improvement of MVA vectors as HIV-1 vaccines...
  79. ncbi Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
    Felipe Garcia
    Hospital Clinic IDIBAPS, Barcelona, Spain
    Vaccine 29:8309-16. 2011
    ..To investigate the safety and immunogenicity of a modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B), a phase-I, doubled-blind placebo-controlled trial was performed...
  80. pmc How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?
    Per Johan Klasse
    Department of Microbiology and Immunology, Cornell University, Weill Cornell Medical College, New York, New York 10065 4896, USA
    AIDS Res Hum Retroviruses 28:1-15. 2012
    ..Drawing on these analyses, we outline strategies for improving Env as a component of a vaccine aimed at inducing strong and sustained NAb responses...
  81. pmc Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 86:4688-92. 2012
    ..These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities...
  82. pmc A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations
    Charani Ranasinghe
    The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia
    Vaccine 29:3008-20. 2011
    ..Our findings further substantiate the importance of vector selection/combination, order and route of delivery when designing effective vaccines for HIV-1...
  83. ncbi HIV vaccine design and the neutralizing antibody problem
    Dennis R Burton
    Departments of Immunology and Molecular Biology, Scripps Research Institute, La Jolla, California, USA
    Nat Immunol 5:233-6. 2004
  84. ncbi The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus
    Gunilla B Karlsson Hedestam
    Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden
    Nat Rev Microbiol 6:143-55. 2008
    ..Efforts to develop broadly neutralizing vaccines against either HIV-1 or influenza virus might establish a paradigm for future vaccines against highly variable pathogens...
  85. pmc The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
    S W Barnett
    Chiron Corporation, Emeryville, California 94608-2916, USA
    J Virol 75:5526-40. 2001
    ....
  86. pmc A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120
    Emma T Crooks
    Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121, USA
    Virology 366:245-62. 2007
    ..Therefore, to make progress toward a more effective VLP-based vaccine, we will need to find ways to refocus the attention of B cells on native trimers...
  87. pmc The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design
    Marinieve Montero
    Department of Molecular Biology and Chemistry, Simon Fraser University, 8888 University Drive, Burnaby V5A 1S6, British Columbia, Canada
    Microbiol Mol Biol Rev 72:54-84, table of contents. 2008
    ..In addition, emerging approaches to vaccine design are presented...
  88. pmc A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules
    Susan Pereira Ribeiro
    Laboratory of Clinical Immunology and Allergy LIM60, Division of Clinical Immunology and Allergy, Department of Medicine, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
    PLoS ONE 5:e11072. 2010
    ..The vaccine may thus be a source of cognate help for HIV-specific CD8+ T cells elicited by conventional immunogens, in a wide proportion of vaccinees...
  89. pmc Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys
    Sampa Santra
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Nat Med 16:324-8. 2010
    ....
  90. pmc Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin
    David J M Lewis
    St George s Vaccine Institute, St George s University of London, London, United Kingdom
    PLoS ONE 4:e6999. 2009
    ..The individual component(s) responsible for paralysis were not identified, and the vaccine was withdrawn...
  91. pmc A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV
    Clarisse Lorin
    Unite des Virus Lents, CNRS URA 1930, Institut Pasteur, Paris, France
    J Virol 78:146-57. 2004
    ..Therefore, recombinant MV vaccines inducing anti-HIV neutralizing antibodies and specific T lymphocytes responses deserve to be tested as a candidate AIDS vaccine...
  92. ncbi Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
    Muhammad Bakari
    Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
    Vaccine 29:8417-28. 2011
    ....
  93. pmc An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study)
    D W Fitzgerald
    Center for Global Health, Weill Cornell Medical College, New York, New York 10021, USA
    J Infect Dis 203:765-72. 2011
    ....
  94. pmc Viral dynamics of acute HIV-1 infection
    S J Little
    Department of Medicine, University of California San Diego, San Diego, California 92103, USA
    J Exp Med 190:841-50. 1999
    ..These measurements provide a basis for comparison of vaccine and other strategies and support the validity of the simian immunodeficiency virus macaque model of acute HIV infection...
  95. ncbi Poxvirus vector-based HIV vaccines
    Giuseppe Pantaleo
    Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland
    Curr Opin HIV AIDS 5:391-6. 2010
    ....
  96. pmc A therapeutic dendritic cell-based vaccine for HIV-1 infection
    Felipe Garcia
    Infectious Diseases Department, Hospital Clinic HIV Development Program in Catalonia, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    J Infect Dis 203:473-8. 2011
    ....
  97. pmc Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine
    Peter Gilbert
    Vaccine Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Infect Dis 202:595-605. 2010
    ..Here we assessed the magnitude and breadth of neutralizing antibody responses in Vax004...
  98. pmc Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study
    Marcel E Curlin
    Vaccine and Infectious Diseases Institute, Fred Hutchinson Cancer Research Center, USA
    AIDS 25:153-8. 2011
    ..We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition...
  99. ncbi Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review
    Marc P Girard
    University Paris 7, French National Academy of Medicine, 39 rue Seignemartin, FR 69008 Lyon, France
    Vaccine 29:6191-218. 2011
    ..This article reviews the state of the art of HIV vaccine development and discusses the formidable scientific challenges met in this endeavor, in the context of a better understanding of the immunopathogenesis of the disease...
  100. pmc Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
    Paul A Goepfert
    Department of Medicine, University of Alabama at Birmingham, AL 35294, USA
    J Infect Dis 203:610-9. 2011
    ..This Phase 1 clinical trial compared the safety and immunogenicity of a rMVA vaccine administered with and without DNA vaccine priming..
  101. pmc Dual neonate vaccine platform against HIV-1 and M. tuberculosis
    Richard Hopkins
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    PLoS ONE 6:e20067. 2011
    ..tuberculosis infant vaccine platform is established. Induction of immune responses against these pathogens soon after birth is highly desirable and may provide a basis for lifetime protection maintained by boosts later in life...

Research Grants64

  1. Infant immunoprophylaxis against a primate lentivirus
    RUTH MARGRIT RUPRECHT; Fiscal Year: 2012
    ..This information may be of vital importance for developing protective AIDS vaccines in the future...
  2. Oral Vaccination for AIDS Prevention in Rhesus Macaques
    Anna Aldovini; Fiscal Year: 2012
    ..Project Narrative: AIDS vaccines may need to engender a substantially greater level and breadth of immunity than other vaccines...
  3. Protective immunity against HIV: the role of IgG subclass and glycosylation
    Donald Forthal; Fiscal Year: 2009
    ..Such studies may lead to methods of improving the ability of antibody to inhibit HIV and eventually to the development of effective HIV/AIDS vaccines.
  4. EIAV Envelope Variation and Vaccine Efficacy
    Ronald C Montelaro; Fiscal Year: 2013
    ..in AIDS vaccine research and can provide important information relevant to the design of candidate human AIDS vaccines. PUBLIC HEALTH RELEVANCE: Development of an effective and practical AIDS vaccine represents a critical need in ..
  5. Macaque model of TB/AIDS co-infection via natural routes of exposure
    Deepak Kaushal; Fiscal Year: 2010
    ..nations, the apparent synergy between AIDS and TB, the spectacular failure of BCG (the anti-TB vaccine) and AIDS vaccines in the pipeline, and drug resistance...
  6. Vaccination against mucosal HIV clade C transmission
    RUTH MARGRIT RUPRECHT; Fiscal Year: 2011
    ..Lastly, fine-tuning the SHIVenvC primate model will allow testing candidate anti-HIV clade C AIDS vaccines in a relevant mucosal challenge system.
  7. HERPESVIRUSES AS VACCINE VECTORS FOR AIDS
    David M Knipe; Fiscal Year: 2010
    ..Development of HSV Vectors as AIDS Vaccines. This project will conduct studies to test several hypotheses regarding the basic properties of herpes simplex ..
  8. New HIV/AIDS vaccines employing inflammatory dendritic cells
    Chae Gyu Park; Fiscal Year: 2012
    ..Successful harnessing of inflammatory dendritic cells also impacts on developing vaccines against other infections and cancer. ..
  9. Virological Synapse and Signaling for Efficient HIV Transmission
    Catarina E Hioe; Fiscal Year: 2013
    ..as they circumvent the unprecedented problem of HIV-1 genetic and antigenic variability, which has hampered the development of efficacious HIV/AIDS vaccines and has led to the emergence of drug-resistant viruses.
  10. Product Development and Manufacture
    ROBERT T MCNALLY; Fiscal Year: 2011
    ..This IPCAVD is developing HIV/AIDS vaccines that use DMA for priming and MVA for boosting (DNA/MVA vaccine) as well as a simpler and ultimately easier to ..
  11. Mechanisms of SIV suppression by CD8+ lymphocytes
    Guido Silvestri; Fiscal Year: 2013
    ..The results generated here will provide correlates of CD8+ lymphocyte-mediated protection to be used to rank and prioritize the development of candidate AIDS vaccines for use in humans.
  12. Reagent Research Support
    Ronald Brown; Fiscal Year: 2009
    ..preparing and/or producing soluble proteins, expression vectors, and gene products (including experimental AIDS vaccines) under current Good Laboratory Practice (cGLP) or Good Manufacturing Practice (cGMP) as appropriate for their ..
  13. Simulator for Primary HIV Replication and Evolution
    Ha Youn Lee; Fiscal Year: 2012
    ..This project will develop a computational simulation that can be used to model this critical phase of virus infection. The model is expected to have important utility in helping to design safe and effective HIV/AIDS vaccines.
  14. Dynamics of SHIV clade C and S mansoni coinfection
    Ruth Ruprecht; Fiscal Year: 2005
    ..This raises concerns that CTL response-based AIDS vaccines may not generate sufficient cellular immunity in individuals with helminth infections...
  15. T CELL IMMUNITY AND SYNTHETIC PEPTIDE AIDS VACCINES
    Amnon Altman; Fiscal Year: 1991
    ..The rational design of AIDS vaccines, an effective form of immunologic intervention in other viral diseases, requires understanding these defense ..
  16. SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY
    Thomas Patterson; Fiscal Year: 2013
    ..SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators...
  17. SVEU - Maintenance of NHPs
    Norman Kneteman; Fiscal Year: 2013
    ..SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators...
  18. RECOMBINANT PICORNAVIRUSES AS AIDS VACCINES
    Raul Andino; Fiscal Year: 2000
    ..abstract_text> ..
  19. Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccines Research a
    Michael Katze; Fiscal Year: 2013
    Nonhuman primate (NHP) models present the opportunity to test a variety of candidate AIDS vaccines, optimizing their ability to elicit immune responses and testing their ability to prevent infection or to control virus replication after ..
  20. HIV VACCINE CLINICAL TRIALS UNIT
    Peter Wright; Fiscal Year: 2006
    ..Evaluation of candidate AIDS vaccines in clinical trials is an essential part of this process and is central to the iterative approach required for ..
  21. DEVELOPMENT OF VSV/HIV RECOMBINANTS AS HIV VACCINES
    John K Rose; Fiscal Year: 2012
    The overall goal of this proposal is to continue development of VSV vectors as AIDS vaccines using the relatively inexpensive mouse and guinea pig models for preliminary evaluation of immune responses...
  22. CONSTRAINED HIV1 GP41 ELDKWA PEPTIDES FOR AIDS VACCINES
    John Taylor; Fiscal Year: 2000
    ..The investigator's structure-activity data should also guide the development of new 2F5-like, HIV-1- neutralizing MAbs, and potent human rhinovirus/HIV-1 chimeras of potential use as live vaccines. ..
  23. NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES
    Mark Feinberg; Fiscal Year: 2003
    ..An Administrative and Data Management Core will coordinate the HIVRAD projects and facilitate communication of ideas and experimental results between investigators. ..
  24. Attenuated recombinant Listeria as oral AIDS vaccine
    Ruth Ruprecht; Fiscal Year: 2003
    ..Because of this natural oral route of Lm infection, Lmdd vectors hold promise as oral AIDS vaccines. In a pilot study, we administered Lmdd-gag orally to two monkeys with short D-ala courses; one monkey was ..
  25. Safer and More Efficacious Recombinant AIDS Vaccines
    Tilahun Yilma; Fiscal Year: 2003
    ..abstract_text> ..
  26. DEVELOPMENT OF A CONTROLLED RELEASE HIV VACCINE ADJUVANT
    TREVOR CASTOR; Fiscal Year: 2000
    ..virus particles yet maintain antigenicity, this technique would also allow for the nanoencapsulation of safe AIDS vaccines intact HIV-1 virions...
  27. MAO/DETECTION OF ANTIBODIES & PROTEINS--ISOLATION OF VIR
    Ranajit Pal; Fiscal Year: 1999
    ..Under this program, a series of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates...
  28. DNA Vaccines With HIV Virus-like Particles
    Ted Ross; Fiscal Year: 2003
    ..antigens to raise cell-mediate immunity, in addition to the humoral immunity that is often elicited by HIV/AIDS vaccines. DNA vaccination can elicit both humoral and cellular immune responses and can confer protection against ..
  29. VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
    David Haas; Fiscal Year: 2006
    ..tract during AIDS; and developing strategies to optimize the design of antiretroviral agents and AIDS vaccines. The Principal Investigator leads an established HIV clinical trials program at Vanderbilt University, and the ..
  30. DEVELOPMENT OF AN AIDS PROTOTYPE VACCINE USING SIV
    Michael Murphey Corb; Fiscal Year: 1993
    ..program will combine the resources and expertise of 4 institutions to develop and evaluate prototype AIDS vaccines using the HIV-related simian immunodeficiency virus (SIV)...
  31. Structure-Based Design of Drugs and Vaccines for Target*
    Edward Arnold; Fiscal Year: 2006
    ..using structural information to guide the design of more potent viral and synthetic immunogens as potential AIDS vaccines. Project 1 (Edward Arnold; CABM, Rutgers) will use X-ray crystallography to determine structures of wild-type ..
  32. COMBINATION IMMUNIZATION AS AN APPROACH TO AIDS VACCINES
    Shiu Lok Hu; Fiscal Year: 2002
    ..Results from this program project will contribute directly to current and future clinical development of AIDS vaccines and enhance our basic understanding of the protective immunity against primate lentiviruses.
  33. Immunostimulatory single cycle SIV Vaccines incorporating TRAF-mediated molecular
    GEOFFREY STONE; Fiscal Year: 2009
    ..new forms of immune-stimulating attenuated SIV that could significantly improve the strength of experimental AIDS vaccines. The result of these studies will establish whether attenuated HIV vaccines can be boosted using key ..
  34. MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE MOD
    RANDALL OWENS; Fiscal Year: 1999
    ..Under this program, a series of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates...
  35. MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE
    RICHARD BRADBURY; Fiscal Year: 2000
    ..Under this program, a series of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates...
  36. EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE MODELS
    Philip Johnson; Fiscal Year: 2000
    ..Under this program, a series of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates...
  37. MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE
    RICHARD BRADBURY; Fiscal Year: 2000
    ..Under this program, a series of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates...
  38. SIMIAN VACCINE EVALUATION UNITS
    Mark Lewis; Fiscal Year: 2012
    ..is to enable the NIAID to use nonhuman primates to conduct studies that advance the development of effective AIDS vaccines, and to a less extent, the development of effective microbicides and other prevention modalities, and immune ..
  39. SIMIAN VACCINE EVALUATION UNIT (SVEU)
    Phillip Markham; Fiscal Year: 2012
    ..is to enable the NIAID to use nonhuman primates to conduct studies that advance the development of effective AIDS vaccines, and to a less extent, the development of effective microbicides and other prevention modalities, and immune ..
  40. RHINOVIRUS--HIV GP41 ELDKWA IMMUNOGENS FOR AIDS VACCINES
    GAIL ARNOLD; Fiscal Year: 2000
    ..abstract_text> ..
  41. SIMIAN VACCINE EVALUATION UNIT (SVEU)
    Michael Agy; Fiscal Year: 2013
    ..is to enable the NIAID to use nonhuman primates to conduct studies that advance the development of effective AIDS vaccines, and to a less extent, the development of effective microbicides and other prevention modalities, and immune ..
  42. MECHANISMS TO ELICIT PROTECTIVE IMMUNITY--AIDS VACCINE
    Frank Tung; Fiscal Year: 1999
    ..SIV provides a model system to investigate the mechanisms of eliciting protective immunity for AIDS vaccines. In animals vaccinated with attenuated SIV, immune responses may be elicited due to continuous expression of ..
  43. Expanding WNPRC Resources for AIDS-Related Research
    Joseph Kemnitz; Fiscal Year: 2007
    ..are to understand the attributes of effective anti-immunodeficiency virus immune responses, develop novel AIDS vaccines, and expand the HIV animal model to include the unique genetic attributes of cynomolgus macaques (Macaca ..
  44. CTL INDUCTION STRATEGIES FOR AIDS VACCINES
    Richard Young; Fiscal Year: 2002
    ..Norman Letvin (Subcontract with Beth Israel Deaconess Medical Center), and for protection against a live challenge with SIV in collaboration with Dr. Michael Wyand (Subcontract with GTC Mason Laboratories). ..
  45. CYTOLYTIC T CELL RESPONSE IN AIDS VACCINE RECIPENTS
    Robert Siliciano; Fiscal Year: 2001
    ..aims of the proposal are: 1) To carry out longitudinal studies defining the human CTL response to candidate AIDS vaccines focusing on the breadth and duration of responses induced by the replication-defective viral vectors that are ..
  46. MOLECULAR AND IMMUNE INTERDICTION OF AIDS
    ARYE RUBENSTEIN; Fiscal Year: 1999
    ..Promising results have been obtained with synthetic AIDS vaccines which for the first time induced both mucosal and systemic humoral and cellular immune responses in human ..
  47. Optimizing the Immunogenicity of MVA-Based AIDS Vaccines
    Mark Feinberg; Fiscal Year: 2007
    ..To address this essential goal, the Emory IPCAVD Program will pursue a complementary series of studies of AIDS vaccines that express consensus multi-subtype, multigene HIV-1 antigens in the context of more highly immunogenic ..
  48. Induction of mucosal immunity by DNA/MVA vaccines
    R Johnson; Fiscal Year: 2004
    ..However, there is little information on the ability of candidate AIDS vaccines to induce T cell responses able to home to mucosal sites...
  49. MINI-HIV VARIANTS AS LIVE-ATTENUATED VACCINE STRAIN
    BENJAMIN BERKHOUT; Fiscal Year: 2001
    ..towards the construction of a next generation of safe, genetically stable HIV-1 variants as live-attenuated AIDS vaccines. The current generation of HIV-1 deletion variants is not permanently attenuated, and therefore unsafe...
  50. An Adjuvanted Therapeutic DNA Vaccine for AIDS
    Michael Murphey Corb; Fiscal Year: 2006
    ..are an integral part of the GSK/PJV clinical co-development efforts for prophylactic and therapeutic AIDS vaccines and will serve three important functions to promote clinical success...